Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of RAIL, Inc. (NASDAQ: GRAL) against certain of their officers and directors for alleged breaches of fiduciary duty.

Shareholders who have continuously held shares since the dates listed below and continue to hold those shares may have standing to seek corporate governance reforms and the return of funds to the company. For a named plaintiff, the firm may also seek a reasonable incentive award, subject to court approval. Representation is on a contingency-fee basis, with no legal fees or expenses payable by participating shareholders.

If you have held GRAIL shares continuously since at least May 12, 2025, and continue to hold those shares, you may have standing to seek corporate governance reforms at GRAIL, including improvements to clinical-trial oversight, disclosure practices, internal controls, and executive accountability.

Complaint Allegations

A previously filed securities class action complaint alleges that GRAIL and certain executives made materially false and misleading statements concerning the likelihood that the NHS-Galleri clinical trial would achieve its primary endpoint of a statistically significant reduction in Stage III and IV cancer diagnoses. On February 19, 2026, GRAIL disclosed that the trial had not achieved that primary endpoint. According to the complaint, the subsequent decline in GRAIL’s stock price caused investor losses.